Intraoral hyperpigmentation due to imatinib mesylate. A review of the literature

Pancholi, Nilesh; Taneja, Pankaj

doi:10.1111/ors.12194

Cited by 4 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathophysiology underlying the pigmentary changes relating to imatinib therapy, and specifically the intraoral hyperpigmentation, remains unclear. Among the implicated mechanisms are the direct inhibition of C-kit, which is physiologically expressed in the oral mucosa, and the deposition of drug metabolite complexes [88,89]. Imatinib is known to target the ATP-binding site of the Bcr-Abl tyrosine kinase, as well as other tyrosine kinases such as platelet-derived growth factor receptor-b, C-kit, and C-ABL [89].…”

Section: Hyperpigmentation (Table 1)mentioning

confidence: 99%

“…Among the implicated mechanisms are the direct inhibition of C-kit, which is physiologically expressed in the oral mucosa, and the deposition of drug metabolite complexes [88,89]. Imatinib is known to target the ATP-binding site of the Bcr-Abl tyrosine kinase, as well as other tyrosine kinases such as platelet-derived growth factor receptor-b, C-kit, and C-ABL [89]. C-kit is a transmembrane growth factor expressed in melanocytes, basal skin cells, and mast cells.…”

Section: Hyperpigmentation (Table 1)mentioning

confidence: 99%

See 1 more Smart Citation

Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy

Villa

Kuten‐Shorrer

2023

IJMS

View full text Add to dashboard Cite

Targeted therapy and immunotherapy have redefined cancer treatment. While they have enhanced tumor response and improved survival rates in many cancer types, toxicities continue to occur, and these often involve the oral cavity. Broadly reported as “mucositis” or “stomatitis,” oral toxicities induced by targeted therapies differ clinically and mechanistically from those associated with conventional chemotherapy. Manifesting primarily as mucosal lesions, salivary gland hypofunction, or orofacial neuropathies, these oral toxicities may nonetheless lead to significant morbidity and impact patients’ quality of life, thereby compromising clinical outcomes. We conclude that familiarity with the spectrum of associated toxicities and understanding of their pathogenesis represent important areas of clinical research and may lead to better characterization, prevention, and management of these adverse events.

show abstract

Section: Hyperpigmentation (Table 1)mentioning

confidence: 99%